II or Class III devices and are subject to premarket approval (PMA) or 510(k) submissions.

EU MDR (2017/745): The EU MDR classifies companion diagnostics as medical devices and establishes requirements for conformity assessment, clinical evaluation, and post-market surveillance.

IVDR (2017/746): Similar to the MDR, the IVDR governs in vitro diagnostic devices and their classifications, specifically focusing on the importance of clinical evidence.

Both the IVDR and MDR emphasize the importance of accurate clinical performance, requiring robust documentation for clinical evaluations tied to the specific biologic or therapeutic product.

Documentation

Proper documentation is a linchpin for successful regulatory submissions. Regulatory agencies require comprehensive data to evaluate the safety and efficacy of companion diagnostics. Critical documentation includes:

• Technical Documentation: A complete dossier including device description, intended use, risk management, and clinical evidence.
• Clinical Evaluation Report (CER): A systematic evaluation of clinical data that demonstrates the device’s performance and safety in relation to specific therapeutic indications.
• Post-Market Surveillance Plan: Ongoing safety tracking and performance assessment post-approval, a regulatory expectation under both the MDR and IVDR.
• Validation of Intended Use: Justifying use in conjunction with a therapeutic product, requiring clear bridging data.

Documentation should be meticulously prepared, adhering to agency guidelines such as the FDA Companion Diagnostic Guidance and the ICH guidelines pertaining to quality, safety, and efficacy.

Review/Approval Flow

The regulatory path for companion diagnostics can vary significantly between regions. Understanding the flow of review and approval processes is critical:

US FDA Approval Process

1. Pre-submission Phase: Engage with the FDA through pre-submission meetings to clarify requirements and seek guidance on the proposed clinical study design.

2. Submission of Premarket Application (PMA) or 510(k): Ensure alignment with the applicable submission requirements based on risk classification.

3. FDA Review: The review process includes evaluation of the scientific validity of the biomarker, data quality, clinical performance, and labeling information.

4. Post-Marketing Requirement: Follow through with obligations for monitoring, including reporting of adverse events.

EU Approval Process (IVDR/MDR)

1. Classification and Notified Body Selection: Classify the device according to IVDR or MDR requirements, and appoint a notified body for conformity assessment.

2. Technical Documentation Submission: Submit the technical dossier to the notified body, ensuring compliance with regulatory standards.

3. Conformity Assessment: The notified body conducts a thorough assessment of documentation and may request additional data or clarification.

4. CE Marking: Following a successful review, the device receives a CE mark, allowing it to be marketed within the EU.

5. Post-Market Surveillance: Implement a post-market surveillance plan to continuously monitor device performance.

Common Deficiencies

A key focus for Regulatory Affairs specialists is to preemptively identify and address potential deficiencies that agencies might encounter during their reviews. Common deficiencies include:

• Insufficient Clinical Evidence: Inadequate data to justify the clinical performance and safety of the companion diagnostic.
• Poor Documentation Quality: Missing or poorly constructed technical documentation, particularly regarding risk management and post-market strategies.
• Lack of Justification for Bridging Data: Failure to provide sufficient rationale for the clinical data extrapolation to bridge between the diagnostic and therapeutic indications.
• Misclassification of Device: Incorrect understanding of device classification leading to non-compliance with necessary regulatory requirements.

To mitigate these issues, it is vital to engage in an iterative review process where documentation is continually refined based on internal assessments and mock submissions. Regular interactions with the regulatory agencies can further improve understanding and compliance with expectations.

RA-Specific Decision Points

Regulatory professionals must make informed decisions throughout the development and submission process. Key decision points include:

Variation vs. New Application

Determining whether to file as a variation of an existing application or as a new application (e.g., a new intended use or significant modification of a device) depends on the nature of the changes:

• If the change is minor and does not impact clinical performance, a variation is generally appropriate.
• If the change involves new biomarker validation or alters the therapeutic connection significantly, a new application may be warranted.

Justification of Bridging Data

When presenting bridging data, regulatory affairs must demonstrate strong scientific rationale connecting the new companion diagnostic to existing clinical evidence for the therapeutic product. This involves:

• Presenting peer-reviewed literature validating the biomarker and technology.
• Establishing parallels in mechanism of action and patient populations.
• Providing a clear and cohesive argument based on comparative effectiveness.

Best Practices for Documentation and Agency Interactions

To enhance the chances of a successful submission, regulatory affairs teams should adopt best practices, including:

• Developing a Comprehensive Roadmap: Early-stage identification of regulatory pathways and requirements can streamline the process significantly.
• Engaging with Stakeholders: Regularly interacting with development and clinical teams to ensure alignment on objectives and requirements is crucial.
• Emphasizing Quality Control: Review and revise documentation iteratively and preemptively address any likely points of concern based on regulatory feedback.
• Educating Internal Teams: Providing training and resources to all stakeholders regarding regulatory requirements and compliance expectations improves overall project efficiency.

Ultimately, regulatory affairs professionals serving in pharmaceutical and biotech sectors need to navigate a complex ecosystem involving clinical, CMC, and commercial interfaces. By fostering a comprehensive understanding of the IVDR, MDR, FDA guidelines, and establishing systematic approaches to documentation and regulatory strategy, organizations can effectively navigate the competitive landscape of advanced therapies and companion diagnostics.

For additional information on requirements, refer to the European Commission’s Guidance on IVDR and the EMA guidelines regarding companion diagnostics.